Biora Therapeutics, Inc.
BIOR · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -89.9% | -41.3% | -37.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 100% | 65.4% | 100% | -13.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -50,709.4% | -4,964.2% | -2,862.7% | -1,530.3% |
| Other Income/Exp. Net | -$0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | $0 | -$0 | -$0 |
| Tax Expense | -$0 | -$0 | $0 | -$0 |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -57,506.3% | 2,033% | -772.9% | -1,767.5% |
| EPS | -5.04 | -0 | -0.14 | -0.62 |
| % Growth | -5,039,900% | 99.9% | 77.4% | – |
| EPS Diluted | -5.04 | 0 | -0.14 | -0.62 |
| Weighted Avg Shares Out | 0 | 36 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 74 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -50,709.4% | 2,270.1% | -236% | -1,579.1% |